PetIQ Stock (NASDAQ:PETQ)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$30.98

52W Range

$15.09 - $31.06

50D Avg

$30.73

200D Avg

$22.52

Market Cap

$919.17M

Avg Vol (3M)

$884.43K

Beta

1.74

Div Yield

-

PETQ Company Profile


PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,121

IPO Date

Jul 21, 2017

Website

PETQ Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Service$133.81M$121.21M-
Product$968.15M$800.30M$825.39M

Fiscal year ends in Dec 23 | Currency in USD

PETQ Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.10M$921.51M$932.53M
Operating Income$37.07K$27.23M$15.87M
Net Income$2.13K$-48.62M$-16.38M
EBITDA$37.07K$62.70M$57.09M
Basic EPS$0.07$-1.67$-0.58
Diluted EPS$0.07$-1.67$-0.58

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 08, 24 | 12:00 AM
Q4 23Feb 29, 24 | 12:07 AM
Q3 23Nov 07, 23 | 8:43 PM

Peer Comparison


TickerCompany
EBSEmergent BioSolutions Inc.
SUPNSupernus Pharmaceuticals, Inc.
RDYDr. Reddy's Laboratories Limited
ANIPANI Pharmaceuticals, Inc.
PAHCPhibro Animal Health Corporation
NBIXNeurocrine Biosciences, Inc.
RGCRegencell Bioscience Holdings Limited
SSICSilver Spike Investment Corp.
DCPHDeciphera Pharmaceuticals, Inc.
BHCBausch Health Companies Inc.
PBHPrestige Consumer Healthcare Inc.
ZTSZoetis Inc.
PCRXPacira BioSciences, Inc.
COLLCollegium Pharmaceutical, Inc.
EVOEvotec SE
EGRXEagle Pharmaceuticals, Inc.